Active Ingredient History

NOW
  • Now
Liposomal daunorubicin is a chemotherapy drug that is FDA approved to treat AIDS related Kaposi's sarcoma. It is also commonly used to treat specific types of leukaemia and non-Hodgkin lymphoma. Liposomal daunorubicin is intravenously administered. It utilizes the liposomal carrier system that provides a favorable pharmacokinetic profile at the site of KS lesions resulting in a 10-fold increase in concentrations compared to that which is achieved with conventional preparations.   Wikipedia

  • SMILES: Cl.COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)C
  • InChIKey: GUGHGUXZJWAIAS-QQYBVWGSSA-N
  • Mol. Mass: 563.99
  • ALogP: 1.03
  • ChEMBL Molecules:
More Chemistry
  • Mechanisms of Action: Missing data
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No
daunoxome | liposomal daunorubicin citrate

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue